PRTA
HealthcareProthena Corporation plc · Biotechnology · $510M
What is Prothena Corporation plc?
Prothena Corporation plc is a late-stage clinical biopharmaceutical company headquartered in Dublin, Ireland. It focuses on discovering and developing novel therapies targeting serious, life-threatening diseases — primarily in the areas of neurodegeneration and amyloid-related conditions.
Prothena advances a pipeline of investigational antibody-based therapies through clinical trials. The company does not yet generate product revenue; instead, it funds operations through collaboration agreements — notably with F. Hoffmann-La Roche and Bristol-Myers Squibb — and capital markets activity. Its programs target misfolded proteins implicated in diseases such as AL amyloidosis, Parkinson's disease, transthyretin amyloidosis, and Alzheimer's disease.
Prothena was founded in 2012 and is headquartered in Dublin, Ireland.
- Birtamimab — Phase III antibody therapy for AL amyloidosis
- Prasinezumab — Phase IIb antibody for Parkinson's disease
- PRX004 — completed Phase I for transthyretin amyloidosis
- PRX005 — Phase I antibody program for Alzheimer's disease
- PRX012 and dual Aß-Tau vaccine — preclinical Alzheimer's programs
Is PRTA a Good Stock to Buy?
UQS Score rates PRTA as Poor overall, reflecting the challenges common to pre-revenue clinical-stage biotechs.
Among the five pillars, Risk is the least concerning — suggesting the company's near-term financial structure is not at an extreme level of distress relative to its stage. That is a modest positive in an otherwise difficult profile.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no commercial products, no durable competitive advantages yet established, and limited near-term revenue visibility. Valuation is rated Elevated, meaning the market may already be pricing in optimistic pipeline outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PRTA pay dividends?
No — Prothena Corporation plc does not currently pay a dividend.
Prothena does not pay a dividend, which is typical for clinical-stage biotechs. All available capital is directed toward funding ongoing clinical trials and research programs. Investors in PRTA are accepting near-term cash burn in exchange for potential long-term upside if pipeline candidates succeed.
When does PRTA report earnings?
Prothena reports financial results on a quarterly cadence, consistent with US-listed equities.
As a pre-revenue clinical company, quarterly reports center on cash runway, operating expenses, and pipeline milestone updates rather than traditional revenue and profit metrics. Collaboration agreement payments from partners like Roche can meaningfully affect reported figures in any given quarter.
For the most recent quarter's results and management commentary, visit Prothena's investor relations page directly.
PRTA Price History
-63.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
PRTA Long-term Outlook
Prothena's fundamental outlook is shaped almost entirely by binary clinical trial outcomes. The Growth pillar is rated Weak, reflecting the absence of near-term commercial revenue and the long timelines typical of late-stage drug development. The Risk pillar sits at Neutral, suggesting the balance sheet provides some runway, but continued cash consumption is a structural feature of this business model. Elevated Valuation means investors are already paying a premium relative to current fundamentals, concentrating the risk-reward profile around pipeline readouts.
Growth drivers
- Positive Phase III data for Birtamimab in AL amyloidosis
- Milestone and royalty payments from Roche and Bristol-Myers Squibb collaborations
- Advancement of early-stage Alzheimer's programs toward clinical proof-of-concept
Key risks
- Clinical trial failure in any lead program could significantly impair the investment thesis
- Elevated valuation leaves limited margin of safety if pipeline timelines extend
- Ongoing cash burn requires continued access to capital markets or partnership funding
PRTA vs Peers
Prothena operates in a crowded small-cap clinical biotech space alongside other pre-revenue or early-revenue companies pursuing niche therapeutic targets.
Crescent Biopharma is an earlier-stage biotech with a distinct therapeutic focus, operating at a smaller scale than Prothena's multi-program pipeline.
Palatin focuses on melanocortin receptor-targeted therapies, giving it a different disease-area profile compared to Prothena's amyloid and neurodegeneration emphasis.
Rigel has reached the commercial stage with approved products, distinguishing it from Prothena's fully pre-revenue pipeline position.
Frequently Asked Questions
What does Prothena Corporation do?
Prothena is a late-stage clinical biopharmaceutical company that develops antibody-based therapies for serious diseases involving misfolded proteins. Its pipeline targets AL amyloidosis, Parkinson's disease, transthyretin amyloidosis, and Alzheimer's disease. The company has no approved products and funds operations primarily through collaboration agreements and capital raises.
Does PRTA pay dividends?
No, Prothena does not pay a dividend. As a pre-revenue clinical-stage company, it reinvests all available capital into its research and development programs. Investors should not expect income distributions in the foreseeable future.
When does PRTA report earnings?
Prothena reports on a quarterly cadence, as is standard for US-listed companies. Because it is pre-revenue, reports focus on operating expenses, cash position, and pipeline updates rather than traditional sales figures. Check Prothena's investor relations page for the current reporting schedule.
Is PRTA a good stock to buy?
UQS Score rates PRTA as Poor, reflecting Weak readings across Quality, Moat, and Growth pillars alongside an Elevated Valuation. That profile signals meaningful risk relative to current pricing. Whether it suits a particular investor depends on their risk tolerance and conviction in the clinical pipeline. The full pillar breakdown is available to Pro members.
Is PRTA overvalued?
The UQS Valuation pillar for PRTA is rated Elevated, suggesting the market is pricing in optimistic pipeline outcomes relative to the company's current fundamentals. For a pre-revenue biotech, valuation is heavily tied to clinical trial expectations rather than traditional earnings-based metrics.
How does PRTA compare to its competitors?
Among small-cap clinical biotechs, Prothena stands out for its multi-program pipeline and high-profile partnerships with Roche and Bristol-Myers Squibb. Peers like Rigel Pharmaceuticals have reached commercial-stage revenue, while others like Palatin and Crescent Biopharma pursue different therapeutic areas at varying stages of development.
What is PRTA's market cap bracket?
Prothena is classified as a small-cap company. This places it in a segment of the market characterized by higher volatility and greater sensitivity to individual clinical trial outcomes compared to large- or mega-cap pharmaceutical companies.
Who founded Prothena Corporation?
Prothena was founded in 2012 as a spin-off from Elan Corporation. Founding leadership included scientists and executives with backgrounds in neurodegenerative disease research. The company has been headquartered in Dublin, Ireland since its establishment.
Is PRTA a long-term quality investment?
As a long-term quality indicator, UQS Score rates PRTA as Poor. The Weak readings on Quality and Moat pillars reflect the absence of durable competitive advantages and commercial revenue at this stage. Long-term quality typically requires demonstrated profitability and business model resilience — characteristics Prothena has not yet established.
What is the main competitive advantage of Prothena?
Prothena's primary differentiator is its scientific expertise in protein misfolding biology and its established partnerships with large pharmaceutical companies. Collaboration agreements with Roche and Bristol-Myers Squibb provide both validation of its science and non-dilutive funding. However, the UQS Moat pillar is rated Weak, reflecting that no durable commercial moat has yet been established.
Is PRTA a growth stock or value stock?
PRTA is best characterized as a speculative clinical-stage biotech rather than a traditional growth or value stock. The UQS Growth pillar is rated Weak due to the absence of commercial revenue, while the Valuation pillar is Elevated — meaning investors are paying a premium based on pipeline potential rather than current financial performance.
Unlock Full PRTA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics driving each pillar
- ✓Compare PRTA against peers on a standardized quality framework
- ✓Track pillar changes as new clinical and financial data arrives
- ✓Screen for higher-quality biotech alternatives across the sector
Pro Analysis
PRTA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 18.0 | 0.8 | 13.0 | 37.5 | 47.1 | 0.0 | +1.7 |
| May 8, 2026 | 16.3 | 0.0 | 13.0 | 37.5 | 36.9 | 0.0 | -3.6 |
| Apr 2, 2026 | 19.9 | 0.8 | 13.0 | 37.5 | 59.4 | 0.0 | — |
PRTA — Pillar Breakdown
Quality
— 0.8/100 (25%)Prothena Corporation plc currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 37.5/100 (20%)Prothena Corporation plc shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 47.1/100 (15%)Prothena Corporation plc has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Prothena Corporation plc appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)Prothena Corporation plc operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PRTA.
Score Composition
Financial Data
More Stock Analysis
How is the PRTA UQS Score Calculated?
The UQS (Unified Quality Score) for Prothena Corporation plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Prothena Corporation plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Prothena Corporation plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.